Complix

1 known investors

Complix develops Cell Penetrating Alphabodies, a protein-based therapeutic platform designed to target intracellular disease targets that are inaccessible to conventional antibodies and small molecule drugs. The company is building a pipeline of therapeutics primarily focused on cancer, autoimmunity, and viral diseases.

Biotech